Cached score snapshot

US.EW · Edwards Lifesciences

110分制 39.8/110;5D動能v2 5/50;排序分 44.8/160 · Incomplete inputs

Ranking score 44.8/160
Main score 39.8/110
5D momentum v2 5/50
Rank #447
Setup grade F 20.7

Score breakdown

避免

Medium twelvedata

Score and price trend

F 20.7 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 04-22 07-23 08-05 08-18 08-28 $74.50$88.91$103.32 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.891 · anchors 120 +1.68% -0.53% / +3.87% 69.8% 3.4% Actual -1.59% · vs median -3.27% · inside 25-75 band
30D observation +7.08% +0.57% / +13.05% 77% 11% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +1.67% -0.30% / +4.11% 70% 3.1% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-04-22 → 2026-08-28 · 351 archived points · 1 Improving turn signal · 7 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 44.8
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 39.8/110 (避免)
5D momentum v2 5/50 (弱)
Score with momentum v2 44.8/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 90.4125
ma50 86.9034
close 85.73
prevClose 87.84
avgVolume20 5008360
volumeRatio 1.04
changePercent -2.4

Metrics snapshot

close 85.73
volume 5224900
changePercent -2.4

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 39.8/110
Main rating 避免
5D momentum v2 5/50
Score with momentum v2 44.8/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.1/5 · 一般

Dimension score 3.1/5
Dimension grade 一般

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0.4
debtPoints 0.5
marginPoints 0.4
turnoverUsdM 447.9307
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0
marketCapPoints 0.5

資金流 — 5.2/20 · 較差

Dimension score 5.2/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 0.8
obvPoints 0.8
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.EW
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 4.6/15 · 較差

Dimension score 4.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 0.8

details

qqq

ma20 718.3455
ma50 719.0052
name QQQ
close 695.33
points 0.4

spy

ma20 745.021
ma50 744.3804
name SPY
close 743.29
points 0.4
source twelvedata+fred
atrPct 2.8753
atrPoints 3
cciPoints 0.8
vixPoints 0
marketTrendPoints 0.8

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 1
catalystCount 0
catalystPoints 2

風險管理 — 6.8/10 · 一般

Dimension score 6.8/10
Dimension grade 一般

Sub-items

position

score 1.6

details

atrPct 2.8753
turnoverUsdM 447.9307
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.EW
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 80.8

strength_details

ma_score 1.5
atr_score 2
rsi_score 2.5
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 5.8
take_profit_price 91.5844
target_multiplier 1.9
technical_strength 1.88
take_profit_percent 6.8
positionPoints 1.6
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.7506
diversificationPoints 2

技術信號 — 16.1/30 · 較差

Dimension score 16.1/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 1.8
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1.8
vcp_reason 波幅收縮(15.3%→11.5%);跌縮量(近10日3日);Ready=N;Confirm=N

vcp_metrics

up_days 3
vol_ref 4861150
down_days 6
vcp_ready false
above_ma50 false
avg_vol_10 4688900
avg_vol_20 4998615
avg_vol_30 4861150
range_pct_10 0.1151
range_pct_20 0.128
range_pct_30 0.153
up_expand_ok false
lookback_used 59
near_20d_high false
contraction_ok true
down_shrink_ok true
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 0.9646
dist_to_20d_high 0.1097
down_shrink_days 3
breakout_level_20d 96.29
vcp_breakout_confirm false
contraction_ratio_10_30 0.7523
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 1.6
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 2/10 · 較差

Dimension score 2/10
Dimension grade 較差

Sub-items

sentiment

score 2

details

source finnhub_news_keyword_model
articleCount 1
negativeHits 0
positiveHits 0
sentimentScoreRaw 0

sentimentData

raw {"id":140768835,"url":"https://finnhub.io/api/news?id=36383ca999e0e2d8c2c95f816b33e0074c375d4162675966285778927441e0f4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing evidence across its aortic, mitral and tricuspid transcatheter valve therapies, including PROGRESS, PARTNER 3, EARLY TAVR, PASCAL and SAPIEN M3 programs. An important takeaway is how the PROGRESS trial’s baseline data on moderate aortic stenosis and long-term durability findings for SAPIEN 3 deepen understanding of earlier, less invasive treatment options for complex...","category":"company","datetime":1782778531,"headline":"Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference"}
raw_source {"id":140923844,"url":"https://finnhub.io/api/news?id=32da7eb77d4992ff3dda71d86dac896e66f7a630f14de4145a045b2bb87a9692","image":"","source":"Benzinga","related":"EW","summary":"Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.","category":"company","datetime":1784203176,"headline":"Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95"}, {"id":140918806,"url":"https://finnhub.io/api/news?id=9ce29e8a103f05ede7f01b3cc8dc6fdfea85964c53b145569e6e0d2ce4bf97e1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"IRVINE, Calif., July 16, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.","category":"company","datetime":1784199900,"headline":"Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026"}, {"id":140923845,"url":"https://finnhub.io/api/news?id=c1bc6bd2c0bc50ee5f997e20172409d41e1d2a6a2254bcba8ee487a35ae39698","image":"","source":"Benzinga","related":"EW","summary":"Mizuho analyst Anthony Petrone maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $105.","category":"company","datetime":1784125451,"headline":"Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105"}, {"id":140900008,"url":"https://finnhub.io/api/news?id=046fa9e725fbd21c8d4cd5bb04dc474ca78380f1c2a35257e14f172cdc026a53","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"The FTC secured the penalty after a court ruled that Edwards failed to comply with antitrust law requirements when it acquired JC Medical in 2024.","category":"company","datetime":1784046736,"headline":"Edwards Lifesciences served $10m penalty over JC Medical acquisition violations"}, {"id":140891355,"url":"https://finnhub.io/api/news?id=7a86d3baa26466a4ba265293463d7e0d19d79051b37231f79e80188e97b14440","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"(Bloomberg) -- The Federal Trade Commission urged a judge to block Henkel AG’s $725 million purchase of part of Pittsburgh Paint Co., saying the deal would harm competition in the liquid-adhesive market by combining two of its biggest players.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Restarts Iran Blockade as US Plans 20% Hormuz ChargeTrump Embraces Australian Retirement System Backed by Larry FinkOpenAI Engineer’s ‘LOL’ Moment Set Stage for Legal Fig","category":"company","datetime":1783969528,"headline":"FTC Says Henkel Deal Would Merge ‘Coke and Pepsi’ of Adhesives"}, {"id":140891424,"url":"https://finnhub.io/api/news?id=2583080fb9cb1dc1a1aa6630bcae89cf976a37974a965d1b7dcfe37c7df91053","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"The artificial heart valve maker will settle allegations it deliberately structured its deal to acquire JC Medical to sidestep a Hart-Scott-Rodino review.","category":"company","datetime":1783962134,"headline":"Edwards will pay $10M to settle FTC charges of skirting antitrust review"}, {"id":140887430,"url":"https://finnhub.io/api/news?id=50fe240da8205292fac353b41a2e4a121dd417b1cab90129dc3c7f2770e48eb0","image":"","source":"Benzinga","related":"EW","summary":"RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $110.","category":"company","datetime":1783937734,"headline":"RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110"}, {"id":140841554,"url":"https://finnhub.io/api/news?id=f808f463d5f0bb22dc96f28672fbc2e037f5d169cc4a1ef4e380aa09c200209e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"The market is focused on today's costs, but the company has already sold a future that looks entirely different.","category":"company","datetime":1783523487,"headline":"The One Number That Could Rewrite the Story for CoreWeave Stock"}, {"id":140840980,"url":"https://finnhub.io/api/news?id=f6b89872007a09af68ad6c31154624cb9a96d205fade79b74bd2350ac6679dce","image":"https://cdn.benzinga.com/files/images/story/2026/07/08/Merck-Logo--Sign-At-Merck-Research-Labor.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay's cut T PT to $24, MS cut ROL PT to $65, GS cut SAM PT to $169, BofA raised ALLY PT to $53, Citi raised EW PT to $110, Wells Fargo raised MRK PT to $150, Jefferies raised ENVA PT.","category":"company","datetime":1783500020,"headline":"Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday"}, {"id":140844806,"url":"https://finnhub.io/api/news?id=e38a7c2046c3ef3ec12c87a213c329f67f1639c81b63531e57a13e266418537b","image":"","source":"Benzinga","related":"EW","summary":"Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $101 to $110.","category":"company","datetime":1783493221,"headline":"Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $110"}, {"id":140825083,"url":"https://finnhub.io/api/news?id=d4831a06a8b6f7f3feb8ad73f380bfa82b004b8eec49a45e787a5b8408bd3d1d","image":"","source":"Benzinga","related":"EW","summary":"Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $93 to $100.","category":"company","datetime":1783339812,"headline":"Evercore ISI Group Maintains Outperform on Edwards Lifesciences, Raises Price Target to $100"}, {"id":140785971,"url":"https://finnhub.io/api/news?id=9417d92376a940320b0658b48d238996e548963863d2897c4d2a6cdaa04c2ccb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences is scheduled to report its second-quarter results soon, and analysts expect a single-digit earnings rise.","category":"company","datetime":1782923534,"headline":"What You Need To Know Ahead of Edwards Lifesciences' Earnings Release"}, {"id":140772402,"url":"https://finnhub.io/api/news?id=29928c6dad2caaf8f5b48d7ed19e8c0bf20103ebebf8dcb587da59e9c1cee1d6","image":"https://cdn.benzinga.com/files/images/story/2026/06/30/Orlando--Fl--Usa---January-20--2022-Dard.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman increased State Street, Evercore raised Owens Corning, Cantor Fitzgerald boosted BioCryst Pharma, BTIG raised Edwards Lifesciences.","category":"company","datetime":1782810296,"headline":"Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday"}, {"id":140774055,"url":"https://finnhub.io/api/news?id=67d042810efc8c2c01c9cd0720b35451092be688f1c6d77f410c83941db8fe06","image":"","source":"Benzinga","related":"EW","summary":"BTIG analyst Marie Thibault maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $100 to $110.","category":"company","datetime":1782806186,"headline":"BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $110"}, {"id":140768835,"url":"https://finnhub.io/api/news?id=36383ca999e0e2d8c2c95f816b33e0074c375d4162675966285778927441e0f4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing evidence across its aortic, mitral and tricuspid transcatheter valve therapies, including PROGRESS, PARTNER 3, EARLY TAVR, PASCAL and SAPIEN M3 programs. An important takeaway is how the PROGRESS trial’s baseline data on moderate aortic stenosis and long-term durability findings for SAPIEN 3 deepen understanding of earlier, less invasive treatment options for complex...","category":"company","datetime":1782778531,"headline":"Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference"}, {"id":140765508,"url":"https://finnhub.io/api/news?id=114499e6dd4eaa6ca7fb68293857493880ef5d632bdbecc410078617b2bb4682","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.","category":"company","datetime":1782754560,"headline":"Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?"}, {"id":140764119,"url":"https://finnhub.io/api/news?id=2558ab0870b5c4bd52b22a6d7cbb6ec5c9eb3d3645adb5a45d03774f7d39dc10","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership","category":"company","datetime":1782750579,"headline":"Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says"}, {"id":140764120,"url":"https://finnhub.io/api/news?id=15115c8ddf386bc50ddc3fb9d01795b6c1cbd80a889b327a585df6d4ea69da48","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.","category":"company","datetime":1782731798,"headline":"Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic"}, {"id":140736627,"url":"https://finnhub.io/api/news?id=617247ab6b79fad40362b749ec64c44ac950f3493e24f2fb8d960847fa1cdeb8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"NEW YORK, June 26, 2026--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.","category":"company","datetime":1782483300,"headline":"Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves"}, {"id":140712255,"url":"https://finnhub.io/api/news?id=a9a0f050cff8fd433fe6026943b71c8fdff53264da5ddef0fa11d04499e6f753","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, today announced the appointment of Ramin Mousavi as Chairman of the Board, effective immediately.","category":"company","datetime":1782295260,"headline":"CardioMech Shareholders Appoint Ramin Mousavi as Chairman of the Board"}, {"id":140692686,"url":"https://finnhub.io/api/news?id=9136e702e7dfcc5d1df79a35985827ce407a733b50c7ff47e028abad22e65c19","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.","category":"company","datetime":1782138480,"headline":"Here's How Macro Trends and Currency Headwind Restrict GMED's Growth"}, {"id":140691146,"url":"https://finnhub.io/api/news?id=843562ed61fee58039a285e36f019315c1d1a32065cd26057a37a4840411af50","image":"https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp","source":"ChartMill","related":"EW","summary":"Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.","category":"company","datetime":1782131700,"headline":"What's going on in today's pre-market session: S&P500 movers"}
data_source finnhub_news_keyword_model
article_count 1
negative_hits 0
positive_hits 0
recomputed_at_score true
sentiment_score_raw 0
source_article_count 22
discarded_article_count 21
sentimentPoints 2

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.1 5/110 62% 3.1
資金流 5.2 20/110 26% 5.2
市場環境 4.6 15/110 30.67% 4.6
催化劑 2 20/110 10% 2
風險管理 6.8 10/110 68% 6.8
技術信號 16.1 30/110 53.67% 16.1
情緒分析 2 10/110 20% 2

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 5/50
ret_5d -0.0703
max_score 50
max_total 50
raw_total 5
vcp_bonus 0
vol_ratio 1.0453
ret_points 0
vol_points 2
range_ratio 0.79
volat_points 0
day_range_pct 0.0205
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.8753
turnoverUsdM 447.9307
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.EW
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 80.8

strength_details

ma_score 1.5
atr_score 2
rsi_score 2.5
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 5.8
take_profit_price 91.5844
target_multiplier 1.9
technical_strength 1.88
take_profit_percent 6.8
positionPoints 1.6
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.7506
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.1/5分
資金流分析總分: 5.2/20分
市場環境分析總分: 4.6/15分
催化劑分析: 2/20分
風險管理總分: 6.8/10分
技術信號分析總分: 16.1/30分
情緒分析: 2/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 100
atr
atr 2.465
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.88
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -128.78
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.0854
kdj
d 30.53
j -11.2
k 16.62
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 超賣或超買風險
score 2
value 36.66
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value 8156600
recentSlope -2628590
previousSlope 3540050
rsi
value 36.12
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 95.1984
position SAR喺價上
distancePct 11.04
previousTrend 下降
ma50
value 86.9034
macd
macd 0.4046
trend 中性偏多
signal 1.3346
histogram -0.9301
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 90.1993
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.04
score 6
avgVolume 5008360
currentVolume 5224900
derived
ma20 90.4125
ma50 86.9034
prevClose 87.84
avgVolume10 4890750
avgVolume20 5008360
changePercent -2.4
avgVolumeForScore 5008360
ma_cross
ma20 90.4125
ma50 86.9034
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 90.46
prevMa50 86.847
spreadPct 4.04
isVolumeBreakout false
bollinger
lower 84.7762
upper 96.0488
position 中間
rsi_short
value 17.06
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.04

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.875306193864458,
        "turnoverUsdM": 447.930677,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.EW",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 80.8,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 5.8,
      "take_profit_price": 91.5844,
      "target_multiplier": 1.9,
      "technical_strength": 1.88,
      "take_profit_percent": 6.8
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.750612387728916,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 44.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 39.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 90.4125,
    "ma50": 86.9034,
    "close": 85.73,
    "prevClose": 87.84,
    "avgVolume20": 5008360,
    "volumeRatio": 1.04,
    "changePercent": -2.4
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": -0.0702743737121786,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 1.0452695396624865,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 0.7900131067066064,
      "volat_points": 0,
      "day_range_pct": 0.020529546249854144,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 44.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.1,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 62,
        "contribution": 3.1
      },
      {
        "raw": 5.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 26,
        "contribution": 5.2
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 16.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 53.67,
        "contribution": 16.1
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 39.8,
    "details": [
      "基本面分析總分: 3.1/5分",
      "資金流分析總分: 5.2/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 16.1/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.1,
      "資金流": 5.2,
      "市場環境": 4.6,
      "情緒分析": 2,
      "技術信號": 16.1,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 1,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.4,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 447.930677,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.EW",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 718.34550435,
                "ma50": 719.0052026400002,
                "name": "QQQ",
                "close": 695.33002,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.021005,
                "ma50": 744.3804017000001,
                "name": "SPY",
                "close": 743.28998,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.875306193864458,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 1,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140768835,
                "url": "https://finnhub.io/api/news?id=36383ca999e0e2d8c2c95f816b33e0074c375d4162675966285778927441e0f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing evidence across its aortic, mitral and tricuspid transcatheter valve therapies, including PROGRESS, PARTNER 3, EARLY TAVR, PASCAL and SAPIEN M3 programs. An important takeaway is how the PROGRESS trial’s baseline data on moderate aortic stenosis and long-term durability findings for SAPIEN 3 deepen understanding of earlier, less invasive treatment options for complex...",
                "category": "company",
                "datetime": 1782778531,
                "headline": "Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference"
              }
            ],
            "raw_source": [
              {
                "id": 140923844,
                "url": "https://finnhub.io/api/news?id=32da7eb77d4992ff3dda71d86dac896e66f7a630f14de4145a045b2bb87a9692",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Truist Securities  analyst Richard Newitter   maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.",
                "category": "company",
                "datetime": 1784203176,
                "headline": "Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95"
              },
              {
                "id": 140918806,
                "url": "https://finnhub.io/api/news?id=9ce29e8a103f05ede7f01b3cc8dc6fdfea85964c53b145569e6e0d2ce4bf97e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., July 16, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.",
                "category": "company",
                "datetime": 1784199900,
                "headline": "Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026"
              },
              {
                "id": 140923845,
                "url": "https://finnhub.io/api/news?id=c1bc6bd2c0bc50ee5f997e20172409d41e1d2a6a2254bcba8ee487a35ae39698",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Mizuho  analyst Anthony Petrone   maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $105.",
                "category": "company",
                "datetime": 1784125451,
                "headline": "Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105"
              },
              {
                "id": 140900008,
                "url": "https://finnhub.io/api/news?id=046fa9e725fbd21c8d4cd5bb04dc474ca78380f1c2a35257e14f172cdc026a53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The FTC secured the penalty after a court ruled that Edwards failed to comply with antitrust law requirements when it acquired JC Medical in 2024.",
                "category": "company",
                "datetime": 1784046736,
                "headline": "Edwards Lifesciences served $10m penalty over JC Medical acquisition violations"
              },
              {
                "id": 140891355,
                "url": "https://finnhub.io/api/news?id=7a86d3baa26466a4ba265293463d7e0d19d79051b37231f79e80188e97b14440",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "(Bloomberg) -- The Federal Trade Commission urged a judge to block Henkel AG’s $725 million purchase of part of Pittsburgh Paint Co., saying the deal would harm competition in the liquid-adhesive market by combining two of its biggest players.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Restarts Iran Blockade as US Plans 20% Hormuz ChargeTrump Embraces Australian Retirement System Backed by Larry FinkOpenAI Engineer’s ‘LOL’ Moment Set Stage for Legal Fig",
                "category": "company",
                "datetime": 1783969528,
                "headline": "FTC Says Henkel Deal Would Merge ‘Coke and Pepsi’ of Adhesives"
              },
              {
                "id": 140891424,
                "url": "https://finnhub.io/api/news?id=2583080fb9cb1dc1a1aa6630bcae89cf976a37974a965d1b7dcfe37c7df91053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The artificial heart valve maker will settle allegations it deliberately structured its deal to acquire JC Medical to sidestep a Hart-Scott-Rodino review.",
                "category": "company",
                "datetime": 1783962134,
                "headline": "Edwards will pay $10M to settle FTC charges of skirting antitrust review"
              },
              {
                "id": 140887430,
                "url": "https://finnhub.io/api/news?id=50fe240da8205292fac353b41a2e4a121dd417b1cab90129dc3c7f2770e48eb0",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "RBC Capital  analyst Shagun Singh   maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $110.",
                "category": "company",
                "datetime": 1783937734,
                "headline": "RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110"
              },
              {
                "id": 140841554,
                "url": "https://finnhub.io/api/news?id=f808f463d5f0bb22dc96f28672fbc2e037f5d169cc4a1ef4e380aa09c200209e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The market is focused on today's costs, but the company has already sold a future that looks entirely different.",
                "category": "company",
                "datetime": 1783523487,
                "headline": "The One Number That Could Rewrite the Story for CoreWeave Stock"
              },
              {
                "id": 140840980,
                "url": "https://finnhub.io/api/news?id=f6b89872007a09af68ad6c31154624cb9a96d205fade79b74bd2350ac6679dce",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/08/Merck-Logo--Sign-At-Merck-Research-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay&#39;s cut T PT to $24, MS cut ROL PT to $65, GS cut SAM PT to $169, BofA raised ALLY PT to $53, Citi raised EW PT to $110, Wells Fargo raised MRK PT to $150, Jefferies raised ENVA PT.",
                "category": "company",
                "datetime": 1783500020,
                "headline": "Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday"
              },
              {
                "id": 140844806,
                "url": "https://finnhub.io/api/news?id=e38a7c2046c3ef3ec12c87a213c329f67f1639c81b63531e57a13e266418537b",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Citigroup  analyst Joanne Wuensch   maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $101 to $110.",
                "category": "company",
                "datetime": 1783493221,
                "headline": "Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $110"
              },
              {
                "id": 140825083,
                "url": "https://finnhub.io/api/news?id=d4831a06a8b6f7f3feb8ad73f380bfa82b004b8eec49a45e787a5b8408bd3d1d",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $93 to $100.",
                "category": "company",
                "datetime": 1783339812,
                "headline": "Evercore ISI Group Maintains Outperform on Edwards Lifesciences, Raises Price Target to $100"
              },
              {
                "id": 140785971,
                "url": "https://finnhub.io/api/news?id=9417d92376a940320b0658b48d238996e548963863d2897c4d2a6cdaa04c2ccb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences is scheduled to report its second-quarter results soon, and analysts expect a single-digit earnings rise.",
                "category": "company",
                "datetime": 1782923534,
                "headline": "What You Need To Know Ahead of Edwards Lifesciences' Earnings Release"
              },
              {
                "id": 140772402,
                "url": "https://finnhub.io/api/news?id=29928c6dad2caaf8f5b48d7ed19e8c0bf20103ebebf8dcb587da59e9c1cee1d6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Orlando--Fl--Usa---January-20--2022-Dard.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Wall Street analysts changed outlook on top names. Wedbush raised Replimune&#39;s price target, Canaccord cut Strategy&#39;s target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman increased State Street, Evercore raised Owens Corning, Cantor Fitzgerald boosted BioCryst Pharma, BTIG raised Edwards Lifesciences.",
                "category": "company",
                "datetime": 1782810296,
                "headline": "Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday"
              },
              {
                "id": 140774055,
                "url": "https://finnhub.io/api/news?id=67d042810efc8c2c01c9cd0720b35451092be688f1c6d77f410c83941db8fe06",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "BTIG  analyst Marie Thibault   maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $100 to $110.",
                "category": "company",
                "datetime": 1782806186,
                "headline": "BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $110"
              },
              {
                "id": 140768835,
                "url": "https://finnhub.io/api/news?id=36383ca999e0e2d8c2c95f816b33e0074c375d4162675966285778927441e0f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing evidence across its aortic, mitral and tricuspid transcatheter valve therapies, including PROGRESS, PARTNER 3, EARLY TAVR, PASCAL and SAPIEN M3 programs. An important takeaway is how the PROGRESS trial’s baseline data on moderate aortic stenosis and long-term durability findings for SAPIEN 3 deepen understanding of earlier, less invasive treatment options for complex...",
                "category": "company",
                "datetime": 1782778531,
                "headline": "Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference"
              },
              {
                "id": 140765508,
                "url": "https://finnhub.io/api/news?id=114499e6dd4eaa6ca7fb68293857493880ef5d632bdbecc410078617b2bb4682",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.",
                "category": "company",
                "datetime": 1782754560,
                "headline": "Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?"
              },
              {
                "id": 140764119,
                "url": "https://finnhub.io/api/news?id=2558ab0870b5c4bd52b22a6d7cbb6ec5c9eb3d3645adb5a45d03774f7d39dc10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership",
                "category": "company",
                "datetime": 1782750579,
                "headline": "Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says"
              },
              {
                "id": 140764120,
                "url": "https://finnhub.io/api/news?id=15115c8ddf386bc50ddc3fb9d01795b6c1cbd80a889b327a585df6d4ea69da48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.",
                "category": "company",
                "datetime": 1782731798,
                "headline": "Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic"
              },
              {
                "id": 140736627,
                "url": "https://finnhub.io/api/news?id=617247ab6b79fad40362b749ec64c44ac950f3493e24f2fb8d960847fa1cdeb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "NEW YORK, June 26, 2026--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.",
                "category": "company",
                "datetime": 1782483300,
                "headline": "Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves"
              },
              {
                "id": 140712255,
                "url": "https://finnhub.io/api/news?id=a9a0f050cff8fd433fe6026943b71c8fdff53264da5ddef0fa11d04499e6f753",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, today announced the appointment of Ramin Mousavi as Chairman of the Board, effective immediately.",
                "category": "company",
                "datetime": 1782295260,
                "headline": "CardioMech Shareholders Appoint Ramin Mousavi as Chairman of the Board"
              },
              {
                "id": 140692686,
                "url": "https://finnhub.io/api/news?id=9136e702e7dfcc5d1df79a35985827ce407a733b50c7ff47e028abad22e65c19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.",
                "category": "company",
                "datetime": 1782138480,
                "headline": "Here's How Macro Trends and Currency Headwind Restrict GMED's Growth"
              },
              {
                "id": 140691146,
                "url": "https://finnhub.io/api/news?id=843562ed61fee58039a285e36f019315c1d1a32065cd26057a37a4840411af50",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.",
                "category": "company",
                "datetime": 1782131700,
                "headline": "What's going on in today's pre-market session: S&P500 movers"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 1,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 22,
            "discarded_article_count": 21
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 16.1,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.8,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.8,
            "vcp_reason": "波幅收縮(15.3%→11.5%);跌縮量(近10日3日);Ready=N;Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 4861150,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 4688900,
              "avg_vol_20": 4998615,
              "avg_vol_30": 4861150,
              "range_pct_10": 0.11512889303627673,
              "range_pct_20": 0.12795987402309592,
              "range_pct_30": 0.1530386095882422,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9645659977577322,
              "dist_to_20d_high": 0.10966870910790323,
              "down_shrink_days": 3,
              "breakout_level_20d": 96.29,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7522865853658538
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.875306193864458,
              "turnoverUsdM": 447.930677,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.EW",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 80.8,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 5.8,
            "take_profit_price": 91.5844,
            "target_multiplier": 1.9,
            "technical_strength": 1.88,
            "take_profit_percent": 6.8
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.750612387728916,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.EW",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 2.465,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.88
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -128.78
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0854
    },
    "kdj": {
      "d": 30.53,
      "j": -11.2,
      "k": 16.62,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 36.66
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 8156600,
      "recentSlope": -2628590,
      "previousSlope": 3540050
    },
    "rsi": 36.12,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 95.1984,
      "position": "SAR喺價上",
      "distancePct": 11.04,
      "previousTrend": "下降"
    },
    "ma50": 86.9034,
    "macd": {
      "macd": 0.40458442023984276,
      "trend": "中性偏多",
      "signal": 1.3346450327860244,
      "histogram": -0.9300606125461817
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 90.1993,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.04,
      "score": 6,
      "avgVolume": 5008360,
      "currentVolume": 5224900
    },
    "derived": {
      "ma20": 90.4125,
      "ma50": 86.9034,
      "prevClose": 87.84,
      "avgVolume10": 4890750,
      "avgVolume20": 5008360,
      "changePercent": -2.4,
      "avgVolumeForScore": 5008360
    },
    "ma_cross": {
      "ma20": 90.4125,
      "ma50": 86.9034,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 90.46,
      "prevMa50": 86.847,
      "spreadPct": 4.04,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 84.7762,
      "upper": 96.0488,
      "position": "中間"
    },
    "rsi_short": 17.06,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.04
    }
  }
}

Raw metrics JSON

{
  "close": 85.73,
  "volume": 5224900,
  "changePercent": -2.4
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.